DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cheilitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCheilitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cheilitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 3 (FGFR3) — FGFR3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K33 · 2.3405 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Cheilitis has no standard classification or work-up. A 2018 review notes that the term covers at least eight subtypes — angular, contact, actinic, glandular, granulomatous, exfoliative, plasma cell and simplex — but nomenclature varies and subtypes are grouped differently. The authors propose a classification based on whether the cheilitis is mainly reversible (simplex, angular/infective, contact/eczematous, exfoliative, drug-related), mainly irreversible (actinic, granulomatous, glandular, plasma cell), or connected to dermatoses and systemic diseases such as lupus, lichen planus, pemphigus, angioedema or xerostomia. The same review states that cheilitis can be an isolated condition or part of systemic diseases like vitamin B12 or iron deficiency anaemia, local infections such as herpes or oral candidiasis, contact reactions to irritants or allergens, sun exposure (actinic cheilitis), or drug intake, especially retinoids.
Cheilitis granulomatosa is a rare inflammatory disorder of unclear aetiology, characterised by recurrent or persistent swelling of one or both lips. A 2001 overview describes it as possibly part of Melkersson-Rosenthal syndrome or a manifestation of Crohn’s disease. A 1997 case report describes a patient with cheilitis granulomatosa who had a positive patch test to salicylate and cinnamaldehyde; after 4.5 months on an exclusion diet avoiding these substances, a 75% reduction in symptoms was reported. No controlled trial data exist for this approach.
A 1999 case report describes a 14-year-old girl with a 2-year history of exquisitely tender, vegetating cheilitis that prevented her from drinking fluids and led to repeated hospitalisation for dehydration and pain management. Lip and skin biopsies and multiple laboratory studies did not yield a definitive diagnosis; after two years the diagnosis of factitial cheilitis was established. A 2022 case report describes a patient with allergic contact cheilitis whose lower lip was dry, cracked, sore and bleeding for four days, with fissures, crusts and desquamation on examination. The patient was prescribed a compounded mixture of hydrocortisone, chemicetin, lanolin and vaseline and was reassessed seven days later. The report states that treatment success depends on proper history and diagnosis, but provides no quantitative outcome data.
What is missing: no randomised trials for any cheilitis subtype; no validated diagnostic criteria; no data on long-term outcomes for the compounded treatment; no evidence base for the exclusion diet beyond a single case; no funding for prospective studies or for developing a consensus classification that could enable stratified trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Differential Diagnosis of Cheilitis – How to Classify Cheilitis?
AbstractAlthough cheilitis as a term describing lip inflammation has been identified and recognized for a long time, until now there have been no clear recommendations for its work-up and classification. The disease may appear as an isolated condition or as part of certain systemic diseases/conditions (such as anemia due to vitamin B12 or iron deficiency) or local infections (e.g., herpes and oral candidiasis). Cheilitis can also be a symptom of a contact reaction to an irritant or allergen, or may be provoked by sun exposure (actinic cheilitis) or drug intake, especially retinoids. Generally, the forms most commonly reported in the literature are angular, contact (allergic and irritant), actinic, glandular, granulomatous, exfoliative and plasma cell cheilitis. However, variable nomenclature is used and subtypes are grouped and named differently. According to our experience and clinical practice, we suggest classification based on primary differences in the duration and etiology of individual groups of cheilitis, as follows: 1) mainly reversible (simplex, angular/infective, contact/eczematous, exfoliative, drug-related); 2) mainly irreversible (actinic, granulomatous, glandular, plasma cell); and 3) cheilitis connected to dermatoses and systemic diseases (lupus, lichen planus, pemphi-gus/pemphigoid group, -angioedema, xerostomia, etc.).
Journal of the European Academy of Dermatology and Venereology · 2001 · 65 citations
Cheilitis granulomatosa
AbstractCheilitis granulomatosa is a rare inflammatory disorder with unclear aetiology. It is a disorder characterized by recurrent or persistent swelling of one or both lips that may be part of the Melkersson-Rosenthal syndrome or may be a manifestation of Crohn's disease. An overview of the clinical features, histopathology, differential diagnosis, management strategies and prognosis of cheilitis granulomatosa is presented and discussed with regard to the literature.
AbstractA 14-year-old adolescent girl presented with a 2-year history of an exquisitely tender, vegetating cheilitis. Because of this, she was unable to drink fluids and was repeatedly hospitalized for dehydration and pain management. Lip and skin biopsies, as well as multiple laboratory studies did not support a definitive diagnosis. After 2 years, a diagnosis of factitial cheilitis was finally established.
Journal of Human Nutrition and Dietetics · 1997 · 3 citations · open access
Cheilitis granulomatosa—an unusual diet for an unusual disorder
AbstractA case of cheilitis granulomatosa, a rare inflammatory disorder of unknown origin is reported. The condition produces non‐tender, persistent swelling of one or both lips and primarily affects young adults. The patient had a positive patch test to salicylate and cinnamaldehyde, and was therefore treated with an exclusion diet avoiding these substances. After 4.5 months on the exclusion diet, a 75% reduction in symptoms was reported.
Combination of hidrocortisone, kemicitine, lanoline and vaseline for allergic cheilitis treatment: case report
AbstractCheilitis is a term to describe inflammation of the vermillion border of the lips. This case report describes compounding with a combination of hydrocortisone,chemicetin, lanolin and vaseline for the treatment of allergic contact cheilitis. Patients with com-plaints of lower lip feeling dry, cracked, sore and bleeding;dryness for 4 days ago. Dry lips getting worse for 2 days ago until bleeding. Objective examination revealed fissures, multiple, well-defined, irregular edges, 1-2 mm long; crusts, regular edges, clear borders, blackish red color; desquamation, multiple, irregular edges, clear boundaries, white color, rough surface. The pa-tient was prescribed a combination of drugs of hydrocortisone, chemicetin, lanoline and vaseline and was instructed on how to use the drug and control it 7 days later. Treatment of allergic contact cheilitis with compounding combination drugs aimed at accelerating healing. However, the success of this case treatment is still based on a proper history so that it chooses a supporting examination and can establish a proper diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
